Saturday 17 October 2026
Export CLGN’s income statement to Excel — free account
CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
3.60
0.08
−2.17%
Follow CLGN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 2 | 6 | 7 | 2 | 5 | 2 | 4 |
P/E ratio |
8.86 | 8.86 | 0.00 | 0.00 | 0.00 | 74.36 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (6.01) | (8.15) | (3.32) | 15.34 | 6.17 | 4.04 | (6.12) | (16.87) |
P/S ratio |
54.76 | 54.76 | 3.67 | 12.26 | 12.09 | 10.43 | 317.34 | 6.29 | 80.07 | 7.21 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.59 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(47.33) | (20.65) | (18.74) | (23.55) | (23.31) | 8.53 | 0.35 | (0.82) | (19.67) | (41.05) |
Beneish M-Score |
— | 0.22 | 3.06 | 2.18 | (1.74) | (2.16) | — | 27.27 | — | (3.20) |
P/Operating CF |
(5.03) | (5.03) | 5.75 | (17.34) | (46.45) | (67.39) | (28.36) | (29.38) | (11.90) | (5.82) |
P/B ratio |
9.90 | 9.90 | 3.40 | 6.95 | 16.57 | 3.61 | 2.94 | 2.43 | 3.06 | 2.81 |
Price to Tangible BV |
9.90 | 9.90 | 3.63 | 6.95 | 16.88 | 3.63 | 2.96 | 2.45 | 3.09 | 2.84 |
EV/Sales |
51.64 | 51.64 | 2.58 | 12.98 | 12.43 | 8.01 | 236.33 | 4.33 | 67.05 | 7.00 |
EV/EBITDA |
51.64 | 51.64 | 0.00 | 0.00 | 0.00 | 149.45 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | (10.64) | (5.28) | (17.14) | 50.07 | (5.16) | (17.17) | (2.45) | (1.76) |
EV/FCF |
0.00 | 0.00 | (6.32) | (4.20) | (15.61) | 132.52 | (4.71) | (12.85) | (2.36) | (1.75) |
Quick Ratio |
1.11 | 3.69 | 2.70 | 1.20 | 1.30 | 14.60 | 9.74 | 8.40 | 4.29 | 2.31 |
Current Ratio |
1.19 | 4.56 | 3.21 | 1.46 | 1.68 | 14.96 | 10.20 | 8.62 | 4.44 | 2.53 |
Net Debt/EBITDA |
0.13 | 0.26 | 1.40 | 0.53 | 0.68 | (51.68) | 1.85 | 4.20 | 0.75 | 0.56 |
Debt/Assets |
1.98% | 45.28% | 0.50% | 0.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.06 | 1.40 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.08 | 0.60 | 0.24 | 0.57 | 0.50 | 0.01 | 0.30 | 0.02 | 0.16 |
Operating CF/Net income |
0.69 | 0.86 | 0.19 | 0.51 | 0.77 | 10.55 | 0.81 | 0.39 | 0.85 | 0.82 |
Capex/Depreciation |
(0.57) | (0.43) | (2.43) | (2.71) | (0.79) | (2.01) | (1.22) | (0.80) | (0.46) | (0.03) |
Interest Coverage |
(62.44) | (54.42) | (1.95) | (2.31) | (164.68) | 0.30 | (53.26) | — | — | — |
| (387.61%) | (294.98%) | (155.43%) | (234.83%) | (134.83%) | 0.96% | (43.73%) | (23.16%) | (79.46%) | (117.56%) | |
| (129.91%) | (98.89%) | (74.21%) | (114.48%) | (53.48%) | 0.76% | (38.04%) | (19.53%) | (62.87%) | (77.90%) | |
ROIC |
(1,044.57%) | (326.75%) | 0.00% | (1,543.49%) | (309.13%) | 2.25% | (410.20%) | (329.47%) | (824.30%) | (5,478.53%) |
Return on Tangible Assets |
(529.40%) | (99.06%) | (98.47%) | (285.38%) | (131.41%) | 0.53% | (53.70%) | (25.47%) | (132.87%) | (207.46%) |
Average Days of Receivables |
4,714.22 | 77.40 | 37.56 | 54.95 | 63.58 | 16.20 | 673.85 | 13.09 | 413.19 | 34.48 |
Research and Development Expense of Revenue |
5,731.33% | 843.66% | 77.32% | 190.42% | 66.24% | 48.79% | 3,429.77% | 95.67% | 2,041.75% | 345.30% |
Selling, General and Administrative Expense of Revenue |
3,772.29% | 497.71% | 74.25% | 157.72% | 76.08% | 37.98% | 2,254.52% | 54.71% | 1,092.43% | 203.80% |
Intangible Assets out of Total Assets |
0.10 | 0.05 | 0.04 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
1,219.28% | 297.92% | 28.60% | 48.53% | 27.28% | 10.21% | 727.09% | 17.67% | 333.79% | 42.13% |
Graham Net Nets |
0.04 | 0.04 | 0.21 | (0.06) | (0.01) | 0.24 | 0.28 | 0.32 | 0.19 | 0.12 |
Graham Number |
0.00 | 45.32 | 0.00 | 0.00 | 0.00 | 47.33 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
11.28% | 11.28% | (21.37%) | (39.81%) | (7.80%) | 1.34% | (17.91%) | (10.25%) | (40.56%) | (67.02%) |
Free Cash Flow Yield |
0.00% | 0.00% | (11.13%) | (25.21%) | (6.59%) | 0.58% | (15.82%) | (5.36%) | (35.45%) | (55.54%) |
Revenue per Share |
0.41 | 1.81 | 11.43 | 4.65 | 8.91 | 15.69 | 0.27 | 9.62 | 0.45 | 1.94 |
Operating CF per Share |
(27.26) | (19.36) | (2.78) | (11.44) | (6.46) | 2.51 | (12.42) | (2.43) | (12.30) | (7.72) |
Capex per Share |
(0.69) | (0.48) | (1.90) | (2.93) | (0.75) | (1.56) | (1.19) | (0.78) | (0.42) | (0.02) |
Free Cash Flow per Share |
(27.95) | (19.85) | (4.67) | (14.37) | (7.22) | 0.95 | (13.61) | (3.20) | (12.72) | (7.74) |
Cash per Share |
5.35 | 19.29 | 12.56 | 7.63 | 4.86 | 43.45 | 26.90 | 23.63 | 10.61 | 4.88 |
Shareholders Equity per Share |
7.26 | 9.84 | 12.36 | 8.20 | 6.50 | 45.26 | 29.26 | 24.88 | 11.76 | 4.98 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.26 | 9.84 | 12.36 | 8.20 | 6.50 | 45.26 | 29.26 | 24.88 | 11.76 | 4.98 |
Free Cash Flow |
(5.63) | (5.29) | (2.05) | (7.16) | (4.97) | 0.95 | (15.01) | (3.65) | (14.57) | (9.45) |
Working Capital |
0.36 | 5.05 | 4.94 | 1.58 | 2.29 | 42.07 | 28.55 | 24.77 | 10.21 | 4.08 |
Capital Expenditures |
(0.14) | (0.13) | (0.83) | (1.46) | (0.52) | (1.56) | (1.32) | (0.89) | (0.48) | (0.03) |
Net Current Asset Value |
(0.34) | 1.00 | 3.84 | (1.62) | (0.69) | 38.98 | 26.17 | 22.24 | 7.94 | 2.04 |
EV/EBIT |
51.64 | 51.64 | 0.00 | 0.00 | 0.00 | 1,926.71 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.67 | 0.27 | 0.17 | 0.63 | 0.08 | 0.10 | 4.40 | 0.08 | 0.94 | 0.01 |
Price to Operating Income |
54.76 | 54.76 | 0.00 | 0.00 | 0.00 | 2,509.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.22 | 0.29 | 0.24 | 0.23 | 0.31 | 0.28 | 0.36 | 0.40 | 0.45 | 0.62 |
Cash ROIC |
(214.81%) | (46.28%) | (18.67%) | (90.51%) | (63.54%) | 1.07% | (24.23%) | (6.60%) | (56.88%) | (78.51%) |
Accounts Receivable Turnover |
0.10 | 0.82 | 16.23 | 5.36 | 8.66 | 17.74 | 0.48 | 23.19 | 1.06 | 5.88 |
Accounts Payable Turnover |
0.00 | 0.01 | 2.26 | 2.58 | 3.68 | 2.19 | 0.37 | 1.88 | 1.76 | 1.13 |
Inventory Turnover |
0.00 | 0.09 | 3.27 | 2.21 | 2.79 | 1.71 | 0.32 | 1.86 | 2.82 | 1.65 |
Average Days of Payables |
0.00 | 20,513.00 | 136.85 | 161.81 | 97.03 | 188.23 | 1,033.86 | 179.66 | 195.42 | 266.65 |
Days of Inventory on Hand |
0.00 | 4,915.33 | 179.09 | 172.50 | 153.44 | 196.79 | 1,304.88 | 130.89 | 98.83 | 250.47 |
Average Receivables |
0.85 | 0.59 | 0.31 | 0.43 | 0.71 | 0.88 | 0.62 | 0.47 | 0.49 | 0.40 |
Average Payables |
1.16 | 1.16 | 0.73 | 0.73 | 0.82 | 0.92 | 1.08 | 1.06 | 0.93 | 0.74 |
Average Inventory |
0.17 | 0.17 | 0.51 | 0.85 | 1.08 | 1.17 | 1.26 | 1.07 | 0.58 | 0.51 |
Average Assets |
6.08 | 6.09 | 8.42 | 9.75 | 10.80 | 31.03 | 44.50 | 35.95 | 26.42 | 14.75 |
Average Common Equity |
2.04 | 2.04 | 4.02 | 4.75 | 4.28 | 24.80 | 38.70 | 30.31 | 20.90 | 9.77 |
Columns are period end dates · fundamentals updated 6 Oct 2026